以己糖激酶Ⅱ为靶点治疗肿瘤的研究进展
作者：张欢;黄思超;蔡绍晖;
Author：
收稿日期： 年卷（期）页码：2011,26(03):-288-290
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：己糖激酶Ⅱ;糖酵解;抗凋亡;耐药;靶向治疗
Key words：
基金项目：国家自然科学基金资助项目(批准号:30973565)
中文摘要
己糖激酶Ⅱ(HKⅡ)作为糖酵解过程的关键限速酶,在肿瘤的存活、增殖、恶性转移及药物耐受等方面发挥着重要的作用。文中就肿瘤中HKⅡ的生物学特征及功能和以HKⅡ为靶点治疗肿瘤的研究进展做一综述。
参考文献
[1]Garber K.Energy deregulation:licensing tumors to grow[J].Sci,2006,312(5777):1158-1159.
[2]Xu RH,Pelicano H,Zhou Y,et al.Inhibition of glycolysis incancer cells:a novel strategy to overcome drug resistance associ-ated with mitochondrial respiratory defect and hypoxia[J].Cancer Res,2005,65(2):613-621.
[3]Pedersen PL.The cancer cell's"power plants"as promising ther-apeutic targets:an overview[J].J Bioenerg Biomembr,2007,39(1):1-12.
[4]Pedersen PL,Mathupala S,Rempel A,et al.Mitochondrial boundtype II hexokinase:a key player in the growth and survival ofmany cancers and an ideal prospect for therapeutic intervention[J].Biochim Biophys Acta,2002,1555(1-3):14-20.
[5]Mathupala SP,Ko YH,Pedersen PL.Hexokinase-2 bound tomitochondria:cancer's stygian link to the"Warburg Effect"anda pivotal target for effective therapy[J].Semin Cancer Biol,2009,19(1):17-24.
[6]Goel A,Mathupala SP,Pedersen PL.Glucose metabolism in canc-er.Evidence that demethylation events play a role in activatingtype II hexokinase gene expression[J].J Biol Chem,2003,278(17):15333-15340.
[7]Pedersen PL.Warburg,me and Hexokinase 2:multiple discover-ies of key molecular events underlying one of cancers'most com-mon phenotypes,the"Warburg effect",i.e.,elevated glycoly-sis in the presence of oxygen[J].J Bioenerg Biomembr,2007,39(3):211-222.
[8]Ahn KJ,Hwang HS,Park JH,et al.Evaluation of the role of hex-okinase type II in cellular proliferation and apoptosis using humanhepatocellular carcinoma cell lines[J].J Nucl Med,2009,50(9):1525-1532.
[9]Kim W,Yoon JH,Jeong JM,et al.Apoptosis-inducing antitumorefficacy of hexokinase II inhibitor in hepatocellular carcinoma[J].Mol Cancer Ther,2007,6(9):2554-2562.
[10]Pastorino JG,Shulga N,Hoek JB.Mitochondrial binding of hex-okinase II inhibits Bax-induced cytochrome c release and apop-tosis[J].J Biol Chem,2002,277(9):7610-7618.
[11]Sun L,Shukair S,Naik TJ,et al.Glucose phosphorylation and mi-tochondrial binding are required for the protective effects of hex-okinases I and II[J].Mol Cell Biol,2008,28(3):1007-1017.
[12]Peng Q,Zhou J,Zhou Q,et al.Silencing hexokinase II gene sensi-tizes human colon cancer cells to 5-fluorouracil[J].Hepatogas-troenterology,2009,56(90):355-360.
[13]Peng Q,Zhou Q,Zhou J,et al.Stable RNA interference of hexoki-nase II gene inhibits human colon cancer LoVo cell growth invitro and in vivo[J].Cancer Biol Ther,2008,7(7):1128-1135.
[14]Ko YH,Smith BL,Wang Y,et al.Advanced cancers:eradicationin all cases using 3-bromopyruvate therapy to deplete ATP[J].Biochem Biophys Res Commun,2004,324(1):269-275.
[15]Vali M,Vossen JA,Buijs M,et al.Targeting of VX2 rabbit livertumor by selective delivery of 3-bromopyruvate:a biodistribu-tion and survival study[J].J Pharmacol Exp Ther,2008,327(1):32-37.
[16]Wang F,Ogasawara MA,Huang P.Small mitochondria-targetingmolecules as anti-cancer agents[J].Mol Aspects Med,2009.
[17]Penso J,Beitner R.Lithium detaches hexokinase from mitochon-dria and inhibits proliferation of B16 melanoma cells[J].MolGenet Metab,2003,78(1):74-78.
[18]Pathania D,Millard M,Neamati N.Opportunities in discovery anddelivery of anticancer drugs targeting mitochondria and cancer cellmetabolism[J].Adv Drug Deliv Rev,2009,61(14):1250-1275.
[19]Chen Z,Zhang H,Lu W,et al.Role of mitochondria-associatedhexokinase II in cancer cell death induced by 3-bromopyruvate[J].Biochim Biophys Acta,2009,1787(5):553-560.
[20]Jae HJ,Chung JW,Park HS,et al.The antitumor effect and hepa-totoxicity of a hexokinase II inhibitor 3-bromopyruvate:in vivoinvestigation of intraarterial administration in a rabbit VX2 hepa-toma model[J].Korean J Radiol,2009,10(6):596-603.
【关闭】
